KRAS and acute myeloid leukemia: In addition, Hamarsheh et al. showed that KRAS mutations promoted NLRP3 inflammasome activation in C57BL/6 mice, while inhibition of NLRP3 inflammasome activation with MCC950 reduced myeloproliferation [9], further supporting that NLRP3 may act as a driver of AML progression in vivo.